Drug Profile

MY 010

Alternative Names: MY010

Latest Information Update: 09 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

09 Oct 2025 Mabylon plans phase I development for MY 010 in 2027 (Mabylon pipeline, October 2025)
09 Sep 2024 Research programme: anti-birch pollen allergy antibodies - Mabylon is available for licensing as of 09 Sep 2024. https://www.mabylon.com/en/Partnering.htm
09 Sep 2024 Preclinical trials in Allergic rhinitis in Switzerland (Parenteral), prior to September 2024 (Mabylon pipeline, September 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com